PEPI-TIDP23-C103: FIRST-IN-HUMAN STUDY TO EXAMINE THE SAFETY, TOLERABILITY, AND PLASMA PHARMACOKINETICS OF INCREASING SINGLE AND REPEATED ORAL DOSES OF TMC558445 AND OF A COMBINED SINGLE DAY DOSING OF ORAL TMC558445 AND ORAL TMC310911 AND ALSO ORAL DARUNAVIR: